Compounded · Dual GLP-1 / GIP receptor agonist

Compounded Tirzepatide

Tirzepatide activates both GLP-1 and GIP receptors, producing greater average weight loss than GLP-1 alone in clinical trials. Compounded versions contain the same active ingredient as Mounjaro® and Zepbound®.

Starting at$249.99/28-day supply

Check If I Qualify Read the FAQs

Form

Vial + syringe (subcutaneous injection)

Frequency

Once weekly

Drug class

Dual GLP-1 / GIP receptor agonist

Who is a candidate for this medication?

Adults 18+ with a BMI of 30+, or 27+ with a weight-related condition.
Have tried GLP-1 mono-therapy or want the highest average efficacy option.
No contraindications to GLP-1/GIP therapy.

Who this medication is not for

Personal or family history of medullary thyroid cancer or MEN 2.
Currently pregnant, trying to conceive, or breastfeeding.
History of pancreatitis or severe GI motility disorders.
Type 1 diabetes.

Dosage overview

Phase	Dose
Weeks 1–4	2.5 mg once weekly.
Weeks 5–8	5 mg once weekly.
Weeks 9+	Titrated up to 7.5–15 mg based on tolerance and goals.

Side effects to know about

Common

· Nausea
· Diarrhea or constipation
· Decreased appetite
· Vomiting
· Injection-site reactions

Serious (call your doctor)

· Pancreatitis
· Gallbladder disease
· Acute kidney injury
· Severe GI reactions

How your care is monitored

Physician check-in at weeks 4, 12, and quarterly.
Weight, blood pressure, side-effect and hydration review at each visit.
Metabolic labs reviewed as clinically indicated.

Pricing

Compounded Tirzepatide starts at $249.99/28-day supply. No insurance required. HSA/FSA eligible. Cancel anytime.

Common questions

Is tirzepatide more effective than semaglutide?

In head-to-head trials (SURMOUNT-1 vs STEP-1), tirzepatide 15 mg produced roughly 20–22% average body weight loss vs ~15% for semaglutide 2.4 mg. Individual results vary.

Why is tirzepatide priced higher?

It's a newer, more complex molecule and dual-target formulation.